SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-164435
Filing Date
2023-06-09
Accepted
2023-06-09 16:05:52
Documents
15
Period of Report
2023-06-08
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d463131d8k.htm   iXBRL 8-K 39866
2 EX-3.1 d463131dex31.htm EX-3.1 11854
6 GRAPHIC g463131g11g40.jpg GRAPHIC 7480
7 GRAPHIC g463131g99u50.jpg GRAPHIC 5755
  Complete submission text file 0001193125-23-164435.txt   200713

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fulc-20230608.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fulc-20230608_lab.xml EX-101.LAB 18723
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fulc-20230608_pre.xml EX-101.PRE 11708
9 EXTRACTED XBRL INSTANCE DOCUMENT d463131d8k_htm.xml XML 3565
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 231005255
SIC: 2834 Pharmaceutical Preparations